| 1. |
|
|
| 2. |
|
|
| 3. |
- Calzetti, D., et al.
(author)
-
Spatially Resolved Dust, Gas, and Star Formation in the Dwarf Magellanic Irregular NGC 4449
- 2018
-
In: Astrophysical Journal. - : American Astronomical Society. - 0004-637X .- 1538-4357. ; 852:2
-
Journal article (peer-reviewed)abstract
- We investigate the relation between gas and star formation in subgalactic regions, similar to 360. pc to similar to 1.5. kpc in size, within the nearby starburst dwarf NGC 4449, in order to separate the underlying relation from the effects of sampling at varying spatial scales. Dust and gas mass surface densities are derived by combining new observations at 1.1. mm, obtained with the AzTEC instrument on the Large Millimeter Telescope, with archival infrared images in the range 8-500 mu m from the Spitzer Space Telescope and the Herschel Space Observatory. We extend the dynamic range of our millimeter (and dust) maps at the faint end, using a correlation between the far-infrared/millimeter colors F(70)/F(1100) (and F(160)/F(1100)) and the mid-infrared color F(8)/F(24) that we establish for the first time for this and other galaxies. Supplementing our data with maps of the extinction-corrected star formation rate (SFR) surface density, we measure both the SFR-molecular gas and the SFR-total. gas relations in NGC 4449. We find that the SFR-molecular. gas relation is described by a power law with an exponent that decreases from similar to 1.5 to similar to 1.2 for increasing region size, while the exponent of the SFR-total. gas relation remains constant with a value of similar to 1.5 independent of region size. We attribute the molecular law behavior to the increasingly better sampling of the molecular cloud mass function at larger region sizes; conversely, the total gas law behavior likely results from the balance between the atomic and molecular gas phases achieved in regions of active star formation. Our results indicate a nonlinear relation between SFR and gas surface density in NGC 4449, similar to what is observed for galaxy samples.
|
|
| 4. |
- Gisselbrecht, Christian, et al.
(author)
-
Rituximab Maintenance Therapy After Autologous Stem-Cell Transplantation in Patients With Relapsed CD20(+) Diffuse Large B-Cell Lymphoma : Final Analysis of the Collaborative Trial in Relapsed Aggressive Lymphoma
- 2012
-
In: Journal of Clinical Oncology. - 0732-183X .- 1527-7755. ; 30:36, s. 4462-4469
-
Journal article (peer-reviewed)abstract
- Purpose The standard treatment for relapsed diffuse large B-cell lymphoma (DLBCL) is salvage chemotherapy followed by high-dose therapy and autologous stem-cell transplantation (ASCT). The impact of maintenance rituximab after ASCT is not known. Patients and Methods In total, 477 patients with CD20(+) DLBCL who were in their first relapse or refractory to initial therapy were randomly assigned to one of two salvage regimens. After three cycles of salvage chemotherapy, the responding patients received high-dose chemotherapy followed by ASCT. Then, 242 patients were randomly assigned to either rituximab every 2 months for 1 year or observation. Results After ASCT, 122 patients received rituximab, and 120 patients were observed only. The median follow-up time was 44 months. The 4-year event-free survival (EFS) rates after ASCT were 52% and 53% for the rituximab and observation groups, respectively (P=.7). Treatment with rituximab was associated with a 15% attributable risk of serious adverse events after day 100, with more deaths (six deaths v three deaths in the observation arm). Several factors affected EFS after ASCT (P<.05), including relapsed disease within 12 months (EFS: 46% v 56% for relapsed disease after 12 months), secondary age-adjusted International Prognostic Index (saaIPI) more than 1 (EFS: 37% v 61% for saaIPI < 1), and prior treatment with rituximab (EFS: 47% v 59% for no prior rituximab). A significant difference in EFS between women (63%) and men (46%) was also observed in the rituximab group. In the Cox model for maintenance, the saaIPI was a significant prognostic factor (P<.001), as was male sex (P=.01). Conclusion In relapsed DLBCL, we observed no difference between the control group and the rituximab maintenance group and do not recommend rituximab after ASCT.
|
|
